NASDAQ: TERNTerns Pharmaceuticals Inc Stock
$4.59+0.05 (+1.1%)
Updated Apr 18, 2024
TERN Price
$4.59
Fair Value Price
$1.11
Market Cap
$296.75M
52 Week Low
$3.26
52 Week High
$14.04
P/E
-3.61x
P/B
1.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$90.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$67M
Beta
0.79
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TERN Overview
Terns Pharmaceuticals Incorporated is a clinical-stage biopharmaceutical company developing small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, andTERN-201, a vascular adhesion protein-1 inhibitor, are in clinical trials for the treatment of NASH. Terns Pharmaceuticals was incorporated in 2016 and is headquartered in Foster City, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TERN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TERN ($4.59) is overvalued by 312.34% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TERN ($4.59) is not significantly undervalued (312.34%) relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TERN due diligence checks available for Premium users.
Be the first to know about important TERN news, forecast changes, insider trades & much more!
TERN News
Valuation
TERN fair value
Fair Value of TERN stock based on Discounted Cash Flow (DCF)
Price
$4.59
Fair Value
$1.11
Overvalued by
312.34%
TERN ($4.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TERN ($4.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TERN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.61x
Industry
15.68x
Market
41.33x
TERN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.16x
Industry
5.76x
TERN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TERN's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.0M
Profit Margin
0%
TERN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$268.5M
Liabilities
$13.2M
Debt to equity
0.05
TERN's short-term assets ($267.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TERN's short-term assets ($267.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TERN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TERN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
$47.2M
Financing
$13.9M
TERN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TERN vs Biotech Stocks
Terns Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.